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Background: Radiologic response of brain tumors is traditionally assessed according to the Macdonald criteria 10
weeks from the start of therapy. Because glioblastoma (GB) responds in days rather than weeks after boron neutron
capture therapy (BNCT) that is a form of tumor-selective particle radiation, it is inconvenient to use the Macdonald
criteria to assess the therapeutic efficacy of BNCT by gadolinium-magnetic resonance imaging (Gd-MRI). Our study
assessed the utility of functional diffusion map (fDM) for evaluating response patterns in GB treated by BNCT.
Methods: The fDM is an image assessment using time-dependent changes of apparent diffusion coefficient (ADC)
in tumors on a voxel-by-voxel approach. Other than time-dependent changes of ADC, fDM can automatically assess
minimum/maximum ADC, Response Evaluation Criteria In Solid Tumors (RECIST), and the volume of enhanced
lesions on Gd-MRI over time. We assessed 17 GB patients treated by BNCT using fDM. Additionally, in order to verify
our results, we performed a histopathological examination using F98 rat glioma models.
Results: Only the volume of tumor with decreased ADC by fDM at 2 days after BNCT was a good predictor for GB
patients treated by BNCT (P value = 0.022 by log-rank test and 0.033 by wilcoxon test). In a histopathological
examination, brain sections of F98 rat glioma models treated by BNCT showed cell swelling of both the nuclei and
the cytoplasm compared with untreated rat glioma models.
Conclusions: The fDM could identify response patterns in BNCT-treated GB earlier than a standard radiographic
assessment. Early detection of treatment failure can allow a change or supplementation before tumor progression
and might lead to an improvement of GB patients’ prognosis.
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Surgery followed by radiation therapy is still the stand-
ard treatment for glioblastoma (GB). The addition of
temozolomide (TMZ) chemotherapy to the standard
treatment has significantly increased the proportion of
patients who survive longer than 2 years [1]. However,
additional progress is needed, as almost half of GB pa-
tients do not survive the first year after diagnosis.* Correspondence: neu046@poh.osaka-med.ac.jp
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reproduction in any medium, provided the orBoron neutron capture therapy (BNCT) has been de-
veloped in the hope of achieving a breakthrough in GB
treatment [2,3]. BNCT is a form of tumor-selective par-
ticle radiation therapy. We have applied BNCT to over
80 GB patients and have reported its survival benefit [4].
Additionally, a phase II multicenter clinical trial of
BNCT is currently underway in Japan. In our substantial
experience of clinical BNCT, we have frequently experi-
enced dramatic reductions in enhanced lesion size
on gadolinium-magnetic resonance imaging (Gd-MRI)
obtained 2 to 7 days after BNCT [2,3]. Assessment ofral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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traditionally accomplished by measuring changes in con-
trast enhancement of tumors at 10 weeks from the start
of therapy using Gd-MRI, using the so-called Macdonald
criteria [5]. The Macdonald criteria guide standard
radiographic assessments, and have been correlated
with survival [5-7]. However, because GB responds in
days rather than weeks after BNCT, it is inconvenient
to use the Macdonald criteria (including the conven-
tional timing) to assess the therapeutic efficacy of
BNCT by Gd-MRI.
On the other hand, the current standard treatment for
GB patients, combined chemo-irradiation with TMZ,
may induce pseudoprogression in 20–30% of cases [8],
defined as an increase of contrast enhancement and/or
edema on MRI without true tumor progression [9]. Also,
full-blown radiation necrosis may be more frequent after
combined chemo-irradiation. Pseudoresponse - namely,
a decrease in contrast enhancement of brain tumors on
MRI without a decrease of tumor activity - is frequent
after treatment with vascular endothelial growth factor
receptor signalling pathway inhibitors. Just as it is diffi-
cult to evaluate response patterns of GB treated by
BNCT, so also cases with pseudoprogression, radiation
necrosis, or pseudoresponse are difficult to assess using
standard radiography because of changes in contrast en-
hancement that do not reflect tumor activity.
Diffusion MRI, which measures the random (Brown-
ian) motion of water, has been proposed as an early bio-
marker for tumor response that does not rely on the
measurement of contrast enhancement [10], and has
been evaluated in preclinical [11,12] and clinical studies
[13-15]. Diffusion MRI measurements are sensitive and
can be used to detect and quantify tissue water diffusion
values, which have been proposed to be related to the
ratio of intracellular water to extracellular water; thus,
changes in apparent diffusion coefficient (ADC) are in-
versely correlated with changes in cellularity. In this sce-
nario, increases in ADC would reflect an increase in the
mobility of water, either through the loss of membrane
integrity or an increase in the proportion of total extra-
cellular fluid with a corresponding decrease in cellular
size or number, as seen with necrosis or apoptosis. In
contrast, decreases in ADC reflect a decrease in free
extracellular water, either through an increase in total
cellular size or number, as can be seen with tumor pro-
gression or tumor cell swelling [16].
Functional diffusion map (fDM) was developed to take
advantage of these principles on a voxel-by-voxel ap-
proach, and have proven to be a powerful tool for
predicting the effect of chemotherapy and radiotherapy
[10,15,17]. An increased ADC has been shown to correl-
ate with a decrease in cellularity as a result of successful
treatment [11,18] and/or radiation necrosis [18]. Otherthan time-dependent changes of ADC, fDM could auto-
matically assess minimum (Min)/maximum (Max) ADC,
Response Evaluation Criteria In Solid Tumors (RECIST),
and the volume of enhanced lesions in response to
BNCT over time.
In the current study, the usefulness of fDM as a pre-
dictive biomarker for GB patients treated with radioche-
motherapy was reported [14,15]. There are no reports
about the usefulness of fDM for GB treated by BNCT.
In order to verify the usefulness of fDM for GB patients
treated by BNCT, we assessed 17 GB patients treated by
BNCT with fDM at 2 days after BNCT and examined a
relationship between all the above factors analyzed by
fDM (time-dependent changes of ADC, Min/Max ADC,
RECIST, and the volume of enhanced lesions) and prog-
nosis of GB patients treated by BNCT. Additionally, we
treated F98 rat glioma models with BNCT and compared
brain sections of the BNCT group with the untreated
group using hematoxylin-eosin (H & E) staining.
Methods
Patient population
We performed a retrospective investigation of clinical
BNCT to evaluate the effects of therapy and adverse
events. From June 2003 to December 2007, we treated a
total of 61 GB patients using BNCT. Because 17 of these
61 GB patients (8 females; 9 males) had diffusion MRI at
pre- and post-BNCT and had contrast enhancement vol-
umes over 0.7 cm3 on Gd-MRI, we were able to assess
them using fDM. Ten patients were newly diagnosed
with GB and 7 patients were recurrent GB cases. The
average age was 56.7 years (36–74 years). The average
survival time from BNCT was 14.5 months (7.2 - 45.9
months). The average volume of contrast enhancement
on Gd-MRIs was 18.8 cm3 (0.7 - 51.4 cm3).
Our treatment for GB patients and boron neutron capture
therapy protocol
Our treatment for GB patients was surgical resection as
much of the tumor as possible, followed by BNCT. Our
BNCT protocol was as follows:
Twelve hours before the neutron irradiation, the pa-
tients were administered 100 mg/kg or none of sodium
borocaptate intravenously for 1 hour. Boronophenylalanine
(BPA) of 250 mg/kg was infused continuously to the pa-
tients for 1 hours or 700 mg/kg was infused continuously
to the patients for 6 hours before the irradiation, and they
were positioned for neutron irradiation in the atomic re-
actor (Kyoto University Research Reactor [KUR] or Japan
Atomic Energy Agency Research Reactor 4). Just after ter-
mination of continuous BPA infusion for 6 hours, neutrons
were irradiated. Between June 2003 and December 2006,
no chemotherapy was applied for any of the patients until
the tumor progression was confirmed histologically or by
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was approved by the Ethical Committee of Osaka Medical
College and also by the Committee for Reactor Medicine in
KUR. The indication of BNCT for each candidate was
discussed by the latter committee.
MRI examinations
All patients underwent pre-BNCT MRI within 20 days
before BNCT and underwent post-BNCT MRI at 2 days
after BNCT. MRI examinations were composed of
T1-weighted images MRI, T2-weighted images, fluid at-
tenuation inversion recovery (FLAIR) images, Gd-T1-
weighted images and diffusion images. MRI was
performed on a 1.5-T MRI system (GE; Wisconsin,
Milwaukee, USA). MRI sequences included T1-weighted
images (TE/TR = 9 ms/2500 ms, slice thickness = 5 mm
with 2.5 mm interslice distance, number of excita-
tions [NEX] = 1, matrix size = 256 × 224, and field of
view [FOV] = 24 cm), T2-weighted images (TE/TR = 103
ms/2500 ms, slice thickness = 5 mm with 2.5 mm
interslice distance, NEX = 1, matrix size = 320 × 192, and
FOV= 24 cm), and FLAIR images (inversion time = 2200
ms, TE/TR = 116.7 ms/8800 ms, slice thickness = 5 mm
with 2.5 mm interslice distance, NEX = 1, matrix size =
256 × 192, and FOV= 24 cm). In addition, Gd-T1-weighted
images (axial: TE/TR = 9 ms/400 ms, slice thickness 5 mm
with 2.5 mm interslice distance, NEX= 1, a matrix size of
256 × 224, and FOV= 24 cm) were acquired after contrast
injection (Magnevist; Berlex; 0.1 mmol/kg) (Table 1).
Diffusion MRI
Diffusion MRI was collected with TE/TR = 79.3 ms/6400
ms, NEX = 1, slice thickness = 5 mm with 0 mm
interslice distance, matrix size = 128 × 192 and a FOV =
24 cm. ADC images were calculated from acquired
DWIs with b = 1000 s/mm2 and b = 0 s/mm2 images
(Table 1). Diffusion images for the three orthogonal di-
rections were combined to calculate an ADC map [20].Table 1 Summarizing the details of MRI sequences
MRI Sequences T1 T2 FLAIR DWI Gd-T1
TR (ms) 2500 4000 8800 4500 400
TE (ms) 9 103 116.7 67.7 9
inversion time (ms) 2200
FOV* (cm) 24 24 24 24 24
slice thickness (mm) 5 5 5 5 5
interslice distance (mm) 2.5 2.5 2.5 0 2.5
frequency matrix 256 320 256 128 256
phase matrix 224 192 192 192 224
NEX** 1 1 1 2 1
scan time (s) 107 144 121 64 94
*FOV = field of view **NEX = number of excitations.fDM analysis
All MRIs were spatially co-registered using the pre-BNCT
Gd-MRI as the reference dataset. This step allowed all im-
ages of a given patient to be viewed and analyzed from a
fixed frame of reference. The co-registration was performed
using a “mutual information for automatic multimodality
image fusion” (MIAMI FUSE) algorithm [21]. After this co-
registration, brain tumors were manually segmented on the
Gd-MRIs by a neurosurgeon (R. H.). These segmentations
were copied into the contemporary diffusion MRIs and
were analyzed using a voxel-by-voxel approach [17,22]. A
minimum of 0.7 cm3 of tumor on Gd-MRI was necessary
for eligibility. If a resection cavity was present, it wasn’t in-
cluded within the regions of interest if circumscribed by
contrast enhancement. Only voxels present in both the
pre-BNCT and post-BNCT tumor volumes were included
for fDM analysis. Individual voxels were stratified into three
categories based on the change in ADC from the pre-
BNCT scan to each time point. Red voxels represent areas
within the tumor where ADC increased (> 55 × 10-5 mm2/
sec); blue voxels represent decreased ADC (< 55 × 10-5
mm2/sec), and green voxels represent no change (Figure 1).
These thresholds represent the 95% confidence intervals for
change in ADC for the uninvolved cerebral hemisphere
[17]. The percentages of the tumor within these three cat-
egories were calculated as VI, VD, and VNC, respectively.
Other than time-dependent changes of ADC, fDM could
automatically assess Min/Max ADC, RECIST, and the vol-
ume of enhanced lesions in response to BNCT over time.
These analyses were performed using fDM analysis soft-
ware (I-Response™-1.0, Cedara software; Ontario Canada).
Representative case
This patient was newly diagnosed GB with 23.2 months of
patients’ survival time after BNCT. Depicted images are sin-
gle slices of Gd-MRI scans at 2 days after BNCT with a
pseudocolor overlay of the fDM. Red voxels indicate re-
gions with a significant rise in ADC at 2 days after BNCT
compared with pre-BNCT, green regions had no changed
ADC, and blue voxels indicate areas of significant decline
in ADC (Figure 1A). The scatter plots display data for the
entire tumor volume and not just for the depicted slice at 2
days after BNCT, with ADC of the pre-BNCT on the x-axis
and ADC at 2 days after BNCT on the y-axis. The central
red line represents unity, and the flanking blue lines repre-
sent the 95% confidence interval (CI) (Figure 1B). Other
than time-dependent changes of ADC, fDM can automatic-
ally assess maximum/minimum ADC, RECIST, and the vol-
ume of enhanced lesions on Gd-MRI over time (Figure 1C).
Correlation with all factors assessed by fDM and survival
time after BNCT
All factors assessed by fDM are composed of VI, VD,
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Figure 1 Representative case: Regions of interests were drawn for tumor image by using anatomical images (A). Red voxels represent
areas within the tumor where ADC increased (> 55 × 10-5 mm2/sec); blue voxels represent decreased ADC (< 55 × 10-5 mm2/sec), and green
voxels represent no change. These thresholds represent the 95% confidence intervals for change in ADC for the uninvolved cerebral hemisphere
(B). VD, VI, VNC, Min/Max ADC, RECIST, and the volume of enhanced lesions on Gd-MRI over time showed 26.8%, 16.7%, 56.5%, 55.0 10
-5 mm2/sec,
251.0 10-5 mm2/sec, 26.3 cm, and 29.8% at 2 days after BNCT, respectively (C).
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was a survival time after BNCT. Survival analysis uti-
lized log-rank and wilcoxon test. Statistical analysis uti-
lized JMP® Pro 10 (SAS Institute Inc., Cary, NC, USA).
Tumor models
F98 rat glioma cells produce infiltrating tumors in the
brains of Fischer rats [23]. The tumors have been
shown to be refractory to a number of treatmentFigure 2 Overall survival of all patients: Median overall survival
was 18.5 months (95% CI; 12.9 - 23.2 months).modalities, including radiation therapy [24]. Based on
their in vivo histology, the F98 rat glioma cells have
been characterized as anaplastic or undifferentiated
glioma [25]. In the present study, F98 rat glioma cells
were kindly obtained from Prof. Barth (Department of
Pathology, the Ohio State University, Columbus, OH,
USA). They were routinely cultivated in our laboratory
in Dulbecco’s Modified Eagle Medium supplemented
with 10% fetal bovine serum and penicillin at 37°C in
an atmosphere of 5% CO2. All the materials for the cul-
ture medium were purchased from Gibco Invitrogen
(Grand Island, NY, USA). Male Fischer rats weighing
200–250 g were anesthetized with an intraperitoneal in-
jection of Nembutal (50 mg/kg) and placed in a stereo-
tactic frame (Model 900, David Kopf Instruments,
Tujunga, CA, USA). A midline scalp incision was made
and the bregma was identified. A 1mm burr hole
was made in the right frontal region of the skull and
a 22-gauge needle attached to a 25-μl syringe was
inserted into the caudate nucleus using the same
stereotactic coordinates, with the needle tip inserted 5
mm into the dura. An injection of 103 F98 rat glioma
cells in 10 μl of serum free medium was administered
at a rate of 1 μl/min. After the infusion, the needle was
left in place for 3 min and the burr hole was then cov-
ered with bone wax.
VD > 12.4%
VD < 12.4%
Figure 4 Survival analysis of VD at 2 days after BNCT: VD greater
than 12.4% at 2 days after BNCT was good response for BNCT
(median survival = 19.3 months; 95% CI = 13.4 - 45.9 months) and
VD 12.4% or less at 2 days after BNCT was nonresponse for BNCT
(median survival = 10.3 months; 95% CI = 7.8 - 13.4 months).
Figure 3 Survival time after BNCT of all patients: Median
survival time after BNCT was 11.2 months (95% CI; 7.8 -
15.3 months).
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At 2 weeks after implantation, the BNCT group was
administered 250 mg/kg body weight of BPA intraven-
ously. An hour and a half after BPA injection, only
the BNCT group was irradiated with neutrons at KUR
during 1 hour. All rats of both the BNCT group and the
untreated group were euthanized by isoflurane 16 days
after implantation (i.e., 2 days after BNCT for the BNCT
group). The rats were perfused and fixed by 10% forma-
lin; then the brains were dehydrated and embedded
in paraffin. The 4-μm sections were stained with
hematoxylin and eosin (H & E) for histopathological in-
vestigation. We compared sections of the BNCT group
with the untreated group using a light microscope
(ECLIPSE80i, Nikon, Japan).Results
MRI examination
In our study, pre-BNCT MRI was performed at 7.9 ± 5.0
(1–20) days before BNCT, and post-BNCT MRI was
performed at 2.5 ± 1.6 (1–8) days after BNCT.Table 2 Survival analysis of all factors assessed by fDM
All fa
VD (%) VI (%) VNC (%) Mi
(10-5
> 12.4 ≤ 12.4 < 3.6 ≥ 3.6 < 74.6 ≥ 74.6 < 70
Median time (M) 19.3 10.3 11.2 12.1 15.3 11 14.3
95% CI 13.4- 7.8- 7.2- 7.8- 6.9- 7.8- 7.8-
(M) 45.9** 13.4** 45.9 15.3 45.9 15.1 22.7**
p value log-rank 0.022* 0.521 0.128 0
wilcoxon 0.033* 0.834 0.35 0
*VD and Min ADC at 2 days after BNCT showed a significant difference using log-ran
the other hand, VD showed no over-lap in 95% CI.Overall survival and survival time after BNCT of all
patients
Median overall survival was 18.5 months (95% CI; 12.9 -
23.2 months) (Figure 2) and median survival time after BNCT
was 11.2 months (95% CI; 7.8 - 15.3 months) (Figure 3).Correlation with all factors assessed by fDM and survival
time after BNCT
VD and Min ADC at 2 days after BNCT showed a sig-
nificant difference using log-rank test and wilcoxon test.
However, Min ADC showed over-lap in 95% CI. On the
other hand, VD showed no over-lap in 95% CI (Table 2).
VD greater than 12.4% at 2 days after BNCT was good
response for BNCT (median survival = 23.2 months;
95% CI = 13.4 - 45.9 months) and VD 12.4% or less at 2
days after BNCT was nonresponse for BNCT (median
survival = 10.3 months; 95% CI = 7.8 - 13.4 months)
(Figure 4). Survival analysis of VD showed a significant





RECIST (cm) Volume reduction rate
of enhanced lesion (%)
≥ 70 < 368 ≥ 368 < 40.3 ≥ 40.3 < −21.1 ≥ −21.1
9.1 11.2 12.1 14.2 10.8 15.1 9.7
7.2- 7.2- 6.9- 7.8- 7.2- 11.2- 7.2-
10.8** 23.2 15.1 45.9 15.1 45.9 15.3
.011* 0.176 0.118 0.143
.045* 0.413 0.223 0.083
k test and wilcoxon test. **However, Min ADC showed over-lap in 95% CI. On
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and the volume reduction rate of enhanced lesions at 2
days after BNCT had no correlation with patients’ sur-
vival time after BNCT (Figure 5, Table 2).
Histopathological examination
Tumor cells in the BNCT group showed swelling of both
the nuclei and the cytoplasm compared with the un-
treated group at 16 days after implantation (i.e., 2 days
after BNCT for the BNCT group) (Figure 6).
Discussion
In 1990, Macdonald et al. reported criteria for response as-
sessment in glioma [5]. Although these criteria have limita-
tions, they have become widely accepted. However, recentVI < 3.6
VI > 3.6
Min ADC < 70






Figure 5 Survival analysis except for VD at 2 days after BNCT: VI, VNC,
lesions at 2 days after BNCT (A, B, D, E, and F, respectively) had no co
test and wilcoxon test. Min ADC at 2 days after BNCT (C) showed a signi
ADC showed over-lap in 95% CI (Table 2).observations have revealed the fundamental limitations of
the Macdonald criteria [26,27]. One limitation of the Mac-
donald criteria is the extended time required to detect
change [5,28,29], about 8 to 10 weeks. Another is the dis-
crepancy between contrast enhancement and tumor
activity. At the core of Macdonald criteria are changes
in contrast enhancement, and all too often, the contrast
enhancement of high-grade tumors is perceived as a meas-
ure of tumor activity. However, contrast enhancement
is nonspecific and primarily reflects a disrupted blood–
brain barrier. Contrast enhancement can be influenced by
changes in corticosteroid dose and radiologic technique
[9,30]. Contrast enhancement can also be induced by a var-
iety of nontumoral processes: inflammation, seizure activity,
postsurgical changes, pseudoprogression, radiation necrosis,VNC < 74.6
VNC > 74.6
Max ADC < 368
Max ADC > 368
Volume reduction rate of 
enhanced lesion  <  -21.1
Volume reduction rate of 




Max ADC, RECIST, and the volume reduction rate of enhanced
rrelation with patients’ survival time after BNCT using log-rank
ficant difference using log-rank test and wilcoxon test. However, Min
A C
DB
Figure 6 Histopathological examination: Tumor cells in the BNCT group showed the cell swelling of both the nuclei and the cytoplasm
(C and D) compared with the untreated group (A and B) at 16 days after the implantation (i.e., at 2 days after BNCT for the BNCT
group). (A and C were at 400-fold. B and D were 1000-fold magnification).
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enhancement cannot be equated with changes in tumor
size or tumor growth/activity.
Recently, several novel imaging methods—positron-emis-
sion tomography, single-photon emission computerized
tomography, MR spectroscopy, and diffusion MRI—have
been evaluated for their ability to assess early therapeutic re-
sponses independently of late changes in enhanced tumor
volume [32,33]. Diffusion MRI detection of cancer treat-
ment response was first successfully reported in a rodent
brain tumor model treated with chemotherapy. Additionally,
Diffusion MRI has been evaluated in preclinical [11,12,34]
and clinical studies [13,34,35]. In 2008, Hamstra et al.
assessed high-grade glioma with functional diffusion map.
They reported that the volume of tumor with increased dif-
fusion by fDM at 3 weeks after the start of radiation therapy
was the strongest predictor of patient survival at 1 year [10].
In our study, VD at 2 days after BNCT was the strongest
predictor of GB patients’ survival time after BNCT.
VD (= the volume of the voxels with decreased ADC com-
pared with pre-BNCT by fDM) indicates that extracellular
free water is relatively decreased for the highest volume of
tumor cells. So, this appearance is attributed to tumor pro-
gression or tumor cell swelling as previously mentioned in
the Background. In our study, day 2 VD was a good predictor
for GB patients treated by BNCT. We attributed this higher
VD to tumor cell swelling rather than tumor progression. Infact, our histopathological study detected tumor cell swelling
in the BNCTgroup compared with the untreated group at 16
days after the implantation (i.e., at 2 days after BNCT for the
BNCTgroup) (Figures 5 and 6). Others have reported tumor
cell swelling in the acute stage after BNCT. Kato et al.
reported the pathological changes of oral squamous cell car-
cinoma at an early stage after BNCT using nude mouse sub-
cutaneous models. They compared a BNCT group with an
untreated group using pathological analysis at 1, 2, and 7 days
after BNCT. Compared to the untreated group, oral squa-
mous cell carcinoma in the BNCT group at all early stages
showed tumor cell swelling on the H & E stained nude
mouse brain sections [36]. Nakagawa et al. reported early
effects of BNCT on C6 rat glioma models. They compared
a BNCT group with an untreated group using pathological
analysis at 4days after BNCT. Compared to the untreated
group, C6 rat glioma cell in the BNCT group showed cell
swelling on the H & E stained rat brain sections [37].
Conclusions
Our study proved that fDM was useful for evaluating the
therapeutic efficacy of BNCT in GB patients treated by
BNCT. Additionally, fDM could identify response patterns
in BNCT-treated GB earlier than a standard radiographic
assessment. Early detection of treatment failure can allow a
change or supplementation before tumor progression and
might lead to an improvement of GB patients’ prognosis.
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